Molecules that interfere with the binding of a tumor necrosis factor receptorwith its ligand, such as a soluble receptor, have proven usefulness in bothbasic research and as therapeutics. The present invention provides improvedsoluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
